What Will Happen.

Thursday July 16, 2016

A couple of interesting updates in the “I’m not an addict” part of the biotech market.

First,

“the FDA document details recommendations for trial design, participant safety, abuse potential, and data collection. In conjunction with the guidance, the FDA and Department of Health and Human Services (HHS) announced a public hearing on the therapeutic use of psychedelics, scheduled for 14 September.”

And second, Lilly acquired Atai Beckley. Why? Don’t know. ATIA did trip both ACC and BOB last year before its run.

So I did a search and found some others related. I am sure there are more I will query our database later.